Sanjuan-Cervero Rafael, Carrera-Hueso Francisco J, Vaquero-Perez Manuel, Montaner-Alonso Daniel
Department of Orthopedic Surgery and Traumatology, Hospital de Denia, Alicante, Spain.
Department of Pharmacy, Hospital Dr. Moliner, Serra, Valencia, Spain.
J Hand Surg Eur Vol. 2020 Jun;45(5):508-512. doi: 10.1177/1753193419900483. Epub 2020 Jan 24.
The aim of this study was to determine whether recurrent Dupuytren's disease after collagenase treatment differs histologically from recurrence in those treated with fasciectomy. We carried out a prospective cohort study of patients with Dupuytren's disease who underwent fasciectomy to treat disease recurrence after previous treatment with collagenase or fasciectomy. The pathologists and statistician were blinded to the previous treatment. Longitudinal biopsy sections were stained with haematoxylin-eosin and the nodular zones were examined. Fifteen patients were studied: nine previously treated with collagenase and six previously treated with fasciectomy. There were no histological differences between the samples from the two groups of patients. Dupuytren's disease recurrences after fasciectomy and collagenase are histologically indistinguishable.
本研究的目的是确定胶原酶治疗后复发性掌腱膜挛缩症在组织学上是否与接受筋膜切除术治疗后的复发情况不同。我们对掌腱膜挛缩症患者进行了一项前瞻性队列研究,这些患者在先前接受胶原酶或筋膜切除术治疗后因疾病复发而接受了筋膜切除术。病理学家和统计学家对先前的治疗情况不知情。纵向活检切片用苏木精-伊红染色,并检查结节区域。共研究了15名患者:9名先前接受过胶原酶治疗,6名先前接受过筋膜切除术治疗。两组患者的样本在组织学上没有差异。筋膜切除术和胶原酶治疗后掌腱膜挛缩症的复发在组织学上无法区分。